Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $3.90
Previous CloseN/A
Volume917.00
Average Volume (3M)14.42K
Market Cap
$291.79M
Enterprise Value$200.90M
Total Cash (Recent Filing)€24.87M
Total Debt (Recent Filing)€627.60K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Sep 25, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding95,662,390
10 Day Avg. Volume26,665
30 Day Avg. Volume14,419
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.81
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.67Price Target Upside306.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInventiva has completed enrollment of the NATiV3 trial, setting the stage for a definitive topline readout and meeting the requirements to access the second tranche of financing.
Financial PerformanceInventiva received additional €126M in funding, providing a cash runway through the third quarter of 2026.
Strategic AdvantageLanifibranor could have a significant competitive advantage in the MASH + T2D patient subpopulation if the effects seen in earlier trials are confirmed in NATiV3.
Bears Say
Market CompetitionLanifibranor could become the second orally-dosed MASH therapy approved by the FDA, exhibiting a stronger efficacy profile compared to resmetirom.
Regulatory ChallengesCompletion of enrollment in NATiV3 supports satisfaction of certain conditions related to the second tranche of approximately €116 million of structured financing.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
5.01% Other Institutional Investors
94.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $1.53 and its highest was $3.90 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $291.79M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 25, 2025 which is in 164 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 26, 2025. The company reported -$1.818 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$1.259.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.73.
How many shares outstanding does Inventiva have?
Inventiva has 95,662,390 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.818 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
---
Inventiva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (306.85% Upside)
$13.67 (306.85% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.5%
Last 30 Days ▲ 33.1%
Last 30 Days ▲ 33.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.29%
12-Months-Change
Fundamentals
Return on Equity
344.74%
Trailing 12-Months
Asset Growth
-45.49%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
---
IVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of lanifibranor, positive trial results, and a strong financial position bolstered by recent financing activities. However, challenges such as workforce reduction and decreased revenue were noted. The sentiment remains cautiously optimistic with strategic partnerships and governance strengthening, despite financial and operational challenges.Read More>---
IVA Stock 12 Month Forecast
Average Price Target
$13.67
▲(306.85% Upside)
Technical Analysis
Oruka Therapeutics
―
Heron Therapeutics
―
RegenXBio
―
Verve Therapeutics
―
Entrada Therapeutics Inc
―
Best Analysts Covering IVA
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+10.58%
reiterated a buy rating 13 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +10.58% per trade.
---